Clinical Trial Update: Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor [Phase 1]

View source ↗

Summary

Phase 1 trial of an autologous dendritic cell vaccine transfected with a patient’s tumor DNA for oral cavity and oropharyngeal cancers was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Oral Cavity Cancer
• Oropharyngeal Cancer

Drugs mentioned

• Autologous dendritic cell vaccine transfected with autologous tumor DNA (autologous dendritic cell vaccine)

Snippet

Sponsor: University of Pittsburgh | Conditions: Primary Advanced Carcinoma of the Oral Cavity or Oropharynx, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: TERMINATED